BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 28, 2026; 32(16): 117799
Published online Apr 28, 2026. doi: 10.3748/wjg.v32.i16.117799
Table 1 Comparison of general data of gastric cancer patients in two groups, n (%)/median (interquartile range)/mean ± SD
Variables
SMIS (n = 20)
ORS (n = 18)
P value
Gender0.164
Male18 (90)13 (72)
Female2 (10)5 (28)
Age (years)61 (55.5, 72)60.5 (46.5 65)0.219
BMI (kg/m2)24.95 (23.6, 27.25)22.95 (21.15, 26.05)0.106
Smoking history7 (35)7 (39)1.000
History of alcohol use10 (50)9 (50)1.000
History of Helicobacter pylori infection3 (15)3 (17)1.000
Hypertension10 (50)6 (33)0.342
Diabetes5 (25)4 (22)1.000
Coronary heart disease, pre-operative blood test4 (20)1 (6)0.344
White blood cells (× 109/L)6.085 (5.515, 7.57)5.57 (4.385, 7.185)0.148
Neutrophils (× 109/L)0.558 ± 0.7210.608 ± 0.9490.076
Lymphocytes (× 109/L)0.335 ± 0.7290.293 ± 0.8530.12
Monocytes (× 109/L)0.0775 (0.065, 0.088)0.074 (0.057, 0.082)0.342
Previous medication history1.000
Anti-inflammatory drugs (anticoagulants, anti-platelet drugs, non-steroidal anti-inflammatory drugs, hormonal drugs)2 (10)1 (5.6)
No anti-inflammatory medication18 (90)17 (94.4)


Write to the Help Desk